이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Johnson & Johnson 관리

관리 기준 확인 2/4

Johnson & Johnson's CEO는 Joaquin Duato, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 $ 28.40M, 5.6% 로 구성됩니다. 5.6% 급여 및 94.4% 보너스(회사 주식 및 옵션 포함). 는 $ 53.04M 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 53.04M. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 4.8 년입니다.

주요 정보

Joaquin Duato

최고 경영자

US$28.4m

총 보상

CEO 급여 비율	5.6%
CEO 임기	2.4yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

업데이트 없음

Recent updates

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

May 16

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

May 03

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

Apr 19

Johnson & Johnson: Buy This Bargain Before It's Gone

Apr 18

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

Apr 11

CEO 보상 분석

Joaquin Duato 의 보수는 Johnson & Johnson 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

보상 대 시장: Joaquin 의 총 보상 ($USD 28.40M )은 US 시장( $USD 13.50M ).

보상과 수익: Joaquin 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Joaquin Duato (61 yo)

2.4yrs

테뉴어

US$28,397,240

보상

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joaquin Duato	CEO & Chairman	2.4yrs	US$28.40m	0.015% $ 53.0m
Joseph Wolk	Executive VP & CFO	5.9yrs	US$13.91m	0.0029% $ 10.3m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.2yrs	US$7.50m	0.0047% $ 16.3m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.4yrs	US$11.00m	0.0064% $ 22.5m
John Reed	Executive Vice President of Innovative Medicine	1.2yrs	US$20.65m	0.00048% $ 1.7m
Robert Decker	Controller & Chief Accounting Officer	4.5yrs	데이터 없음	0.00082% $ 2.9m
James Swanson	Executive VP & Chief Information Officer	4.6yrs	데이터 없음	0.00061% $ 2.1m
Jessica Moore	Vice President of Investor Relations	2.6yrs	데이터 없음	데이터 없음
Dirk Brinckman	Chief Compliance Officer	no data	데이터 없음	데이터 없음
Elizabeth Forminard	Executive VP & Chief Legal Officer	1.7yrs	데이터 없음	0.00035% $ 1.2m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	데이터 없음	데이터 없음
William Hait	Executive VP	17.4yrs	데이터 없음	0.0016% $ 5.6m

4.5yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: JNJ 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joaquin Duato	CEO & Chairman	2.4yrs	US$28.40m	0.015% $ 53.0m
D. Davis	Independent Director	10yrs	US$350.00k	0% $ 0
Anne Mulcahy	Independent Director	15.4yrs	US$410.00k	0.00034% $ 1.2m
Hubert Joly	Independent Director	4.5yrs	US$320.00k	0.00021% $ 736.1k
Marillyn Hewson	Lead Independent Director	5.2yrs	US$360.00k	0.00012% $ 420.6k
Paula Johnson	Independent Director	1.3yrs	US$352.97k	0.000010% $ 35.1k
Mark McClellan	Independent Director	10.7yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.3yrs	US$340.00k	0.000040% $ 140.2k
Jennifer Doudna	Independent Director	6.2yrs	US$320.00k	0% $ 0
Mark Weinberger	Independent Director	4.5yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	3.5yrs	US$340.00k	0% $ 0

4.8yrs

평균 재임 기간

63.5yo

평균 연령

경험이 풍부한 이사회: JNJ 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Johnson & Johnson 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Recent updates

Johnson & Johnson Announces Positive Topline Results from the Pivotal Phase 3 GRAVITI Investigational Study of TREMFYA® Subcutaneous (SC) Induction Therapy in Adult Patients with Moderate to Severe Active Crohn's Disease

Beasley Allen and Levin Papantonio Announces Class Action Lawsuit Against Johnson & Johnson

Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma

There's Reason For Concern Over Johnson & Johnson's (NYSE:JNJ) Price

New major risk - Revenue and earnings growth

Johnson & Johnson to Report Q3, 2024 Results on Oct 15, 2024

Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers.

Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes

Johnson & Johnson: Market Will Regret The Overreaction

Johnson & Johnson: Vital Signs Decent, A Compelling Value Case

Johnson & Johnson Announces the First Phase 3 Results for Tremfa® (Guselkumab) in Adult Patients with Moderate to Severe Active Crohn's Disease Program

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Proteologix, Inc. for $850 million.

Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Updated Results from an Open-Label, Multicenter, Multi-Cohort Phase 1 Study of the Safety and Efficacy of TAR-210

Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson (NYSE:JNJ) Will Pay A Larger Dividend Than Last Year At $1.24

First quarter dividend increased to US$1.24

Johnson & Johnson: Buy This Bargain Before It's Gone

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Johnson & Johnson Revises Earnings Guidance for the Full Year of 2024

Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies

Johnson & Johnson Q1 Earnings Preview: Shockwave Could Be A Good Fit Despite Headwinds

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령